Pharmacodynamic Analysis of the Anticoagulant Effects of Idraparinuxparinux after Termination of 6 and 12 Months Therapy for Prevention of Recurrent Venous Thromboembolism: Observations after the vanGogh Trials
| العنوان: | Pharmacodynamic Analysis of the Anticoagulant Effects of Idraparinuxparinux after Termination of 6 and 12 Months Therapy for Prevention of Recurrent Venous Thromboembolism: Observations after the vanGogh Trials |
|---|---|
| المؤلفون: | Ingrid Joerg, Christina Giese, Gerd Mikus, Job Harenberg, Christel Weiss, Antje Hagedorn |
| المصدر: | Blood. 110:1883-1883 |
| بيانات النشر: | American Society of Hematology, 2007. |
| سنة النشر: | 2007 |
| مصطلحات موضوعية: | business.industry, medicine.drug_class, Idraparinux, Immunology, Antithrombin, Anticoagulant, Warfarin, Renal function, Cell Biology, Hematology, Placebo, Biochemistry, Pharmacodynamics, Anesthesia, Medicine, Biological half-life, business, medicine.drug |
| الوصف: | Idraparinux is a synthetic, polymethylated O-methyl, O-sulphate pentasaccharide with a higher affinity to antithrombin and has been investigated in patients with acute venous thromboembolism (VTE) for prophylaxis of recurrent events (vanGogh studies). 2.5 mg Idraparinux was given once weekly subcutaneously in patients with a creatinine clearance > 30 ml/min and continoued with 1.5 mg Idraparinux from the second injection in patients with lower creatinine clearance. This treatemnt was randomly compared to bodyweight adjusted enoxaparin followed by INR-adjusted warfarin for 3 to 6 months to prevent symptomatic recurrent VTE. The vanGogh extension trial randomised patients of the vanGogh trials or other patients with a 3 to 6 months course of warfarin after an initial first event of VTE for an additional double blind 6 months therapy of Idraparinux compared to placebo. The pharmacodynamic parameters of factor Xa (aXa) inhibition using the S2222 chromogenic substrate and Heptest assay were determined from plasma samples of 23 patients obtained after termination of a 6 or 12 months (Idraparinux for 6 months each in the DVT/PE and extension studies) therapy up to 15 months. The elimination half life of Idraparinux was 60±14 days (d, mean+SD) after termination of therapy (S2222) and 107±34 d (Heptest, p |
| تدمد: | 1528-0020 0006-4971 |
| DOI: | 10.1182/blood.v110.11.1883.1883 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::1a15b952cc05ef024bc8f9202d43eac6 https://doi.org/10.1182/blood.v110.11.1883.1883 |
| رقم الانضمام: | edsair.doi...........1a15b952cc05ef024bc8f9202d43eac6 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15280020 00064971 |
|---|---|
| DOI: | 10.1182/blood.v110.11.1883.1883 |